Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer.
Journal
Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
15
09
2019
revised:
07
02
2020
accepted:
18
02
2020
pubmed:
7
5
2020
medline:
1
9
2020
entrez:
7
5
2020
Statut:
ppublish
Résumé
Nanobodies, derived from camelid antibodies made of only heavy chains, are the smallest, biologic, antigen-binding fragments (~15kDa) with faster pharmacokinetics and better tumor penetration efficiency than standard antibodies. The present study evaluates the efficacy of a fluorescent, anti-carcinoembryonic antigen (CEA) nanobody for rapid tumor labeling in an orthotopic mouse model of pancreatic cancer. Anti-CEA or control nanobodies were conjugated with the near-infrared fluorophore IRDye 800CW. Fragments of BxPC-3 (high-CEA expressing) or MiaPACA-2 (low-CEA expressing) human pancreatic cancer cell lines were orthotopically implanted into the pancreatic tail of nude mice. After tumors reached 7 to 10 mm in size, 2 nmol anti-CEA or control nanobody-IRDye800CW were injected intravenously. Mice were imaged at various time points hours post-injection. Anti-CEA nanobodies clearly labeled BxPC3 orthotopic pancreatic tumors 3 hours after injection. The signal was present as early as 15 minutes after injection and was robust at 1 to 3 hours after injection with a tumor-to-background ratio of 2.66. In contrast, there was very low accumulation in the low CEA-expressing, MiaPACA2 pancreatic orthotopic tumors. The fluorophore-conjugated nanobody was specific for CEA-expressing tumors, while the control nanobody did not show any tumor-specific signal. Both nanobodies had strong kidney uptake as expected for small-molecule probes. The fluorescence signal was detectable using 2 clinical, Food and Drug Administration-approved, 800 nm imaging devices as well as small animal imaging systems. This anti-CEA, nanobody-based, fluorescent probe labeled pancreatic orthotopic tumors within 15 minutes of intravenous injection. Fluorescent anti-CEA nanobodies have labeling kinetics that approach the speed of nonspecific dyes such as indocyanine green but with the specificity of antibodies. The use of fluorescently-labeled, intact antibodies leads to a labeling delay of 48 to 96 hours between probe administration and the necessarily delayed time of operation, which can be avoided with nanobodies. The kinetics of a nanobody-based probe makes it a practical agent for same-day, patient administration and fluorescence-guided surgery.
Sections du résumé
BACKGROUND
Nanobodies, derived from camelid antibodies made of only heavy chains, are the smallest, biologic, antigen-binding fragments (~15kDa) with faster pharmacokinetics and better tumor penetration efficiency than standard antibodies. The present study evaluates the efficacy of a fluorescent, anti-carcinoembryonic antigen (CEA) nanobody for rapid tumor labeling in an orthotopic mouse model of pancreatic cancer.
METHODS
Anti-CEA or control nanobodies were conjugated with the near-infrared fluorophore IRDye 800CW. Fragments of BxPC-3 (high-CEA expressing) or MiaPACA-2 (low-CEA expressing) human pancreatic cancer cell lines were orthotopically implanted into the pancreatic tail of nude mice. After tumors reached 7 to 10 mm in size, 2 nmol anti-CEA or control nanobody-IRDye800CW were injected intravenously. Mice were imaged at various time points hours post-injection.
RESULTS
Anti-CEA nanobodies clearly labeled BxPC3 orthotopic pancreatic tumors 3 hours after injection. The signal was present as early as 15 minutes after injection and was robust at 1 to 3 hours after injection with a tumor-to-background ratio of 2.66. In contrast, there was very low accumulation in the low CEA-expressing, MiaPACA2 pancreatic orthotopic tumors. The fluorophore-conjugated nanobody was specific for CEA-expressing tumors, while the control nanobody did not show any tumor-specific signal. Both nanobodies had strong kidney uptake as expected for small-molecule probes. The fluorescence signal was detectable using 2 clinical, Food and Drug Administration-approved, 800 nm imaging devices as well as small animal imaging systems.
CONCLUSION
This anti-CEA, nanobody-based, fluorescent probe labeled pancreatic orthotopic tumors within 15 minutes of intravenous injection. Fluorescent anti-CEA nanobodies have labeling kinetics that approach the speed of nonspecific dyes such as indocyanine green but with the specificity of antibodies. The use of fluorescently-labeled, intact antibodies leads to a labeling delay of 48 to 96 hours between probe administration and the necessarily delayed time of operation, which can be avoided with nanobodies. The kinetics of a nanobody-based probe makes it a practical agent for same-day, patient administration and fluorescence-guided surgery.
Identifiants
pubmed: 32370916
pii: S0039-6060(20)30105-7
doi: 10.1016/j.surg.2020.02.020
pmc: PMC7311276
mid: NIHMS1573418
pii:
doi:
Substances chimiques
Fluorescent Dyes
0
Single-Domain Antibodies
0
Types de publication
Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-91Subventions
Organisme : BLRD VA
ID : I01 BX003856
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA121938
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA109949
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132971
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA109949
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Ann Surg Oncol. 2018 Jul;25(7):1880-1888
pubmed: 29667116
Hepatogastroenterology. 2015 May;62(139):715-22
pubmed: 26897960
Ann Surg. 2005 May;241(5):715-22, discussion 722-4
pubmed: 15849507
World J Surg. 2008 Jun;32(6):1057-66
pubmed: 18264829
Theranostics. 2014 Aug 15;4(11):1072-84
pubmed: 25250092
J Nucl Med. 2010 Jul;51(7):1099-106
pubmed: 20554727
J Am Coll Surg. 2014 Jun;218(6):1201-6
pubmed: 24698487
IDrugs. 2010 Aug;13(8):543-9
pubmed: 20721825
Leukemia. 2014 Feb;28(2):444-7
pubmed: 24166214
Hepatogastroenterology. 2012 Sep;59(118):1994-9
pubmed: 22369743
Br J Surg. 2015 Jan;102(2):e56-72
pubmed: 25627136
Oncotarget. 2018 Dec 18;9(99):37333-37342
pubmed: 30647873
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Quant Imaging Med Surg. 2012 Sep;2(3):177-87
pubmed: 23256079
Chem Biol. 2013 Feb 21;20(2):161-7
pubmed: 23438745
Expert Rev Anticancer Ther. 2016;16(1):71-81
pubmed: 26567611
Cancer Res. 2004 Apr 15;64(8):2853-7
pubmed: 15087403
Ann Surg Oncol. 2018 Apr;25(4):1079-1085
pubmed: 29372363
Ann Surg Oncol. 2014 Apr;21(4):1405-11
pubmed: 24499827
Mol Pharm. 2017 Apr 3;14(4):1145-1153
pubmed: 28245129
J Surg Oncol. 2017 Dec;116(7):898-906
pubmed: 28628728
Cancer Gene Ther. 2015 Jul;22(7):344-50
pubmed: 26088297
J Surg Oncol. 2016 Mar;113(3):283-8
pubmed: 26603829
Immunopharmacol Immunotoxicol. 2016;38(1):21-8
pubmed: 26551147
Cell Cycle. 2009 Feb 1;8(3):505-6
pubmed: 19176997
Bioconjug Chem. 2014 May 21;25(5):979-88
pubmed: 24815083
J Am Coll Surg. 2012 Jul;215(1):126-35; discussion 135-6
pubmed: 22632917
Expert Rev Anticancer Ther. 2018 Jul;18(7):651-662
pubmed: 29768067
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5645-9
pubmed: 1608975
Mol Imaging Biol. 2018 Jun;20(3):361-367
pubmed: 29090412
Methods. 2014 Jan 1;65(1):139-47
pubmed: 24091005
J Nucl Med. 2016 Jan;57(1):144-50
pubmed: 26449839